ATE445164T1 - Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie - Google Patents
Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapieInfo
- Publication number
- ATE445164T1 ATE445164T1 AT00401778T AT00401778T ATE445164T1 AT E445164 T1 ATE445164 T1 AT E445164T1 AT 00401778 T AT00401778 T AT 00401778T AT 00401778 T AT00401778 T AT 00401778T AT E445164 T1 ATE445164 T1 AT E445164T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- treating
- tumor cells
- detecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00401778A EP1167975B1 (de) | 2000-06-22 | 2000-06-22 | Zusammensetzungen und Methoden zum Nachweis, Behandeln oder Vorhersagen der Antwort von Brust Tumorzellen auf eine Endocrin-Therapie |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE445164T1 true ATE445164T1 (de) | 2009-10-15 |
Family
ID=8173738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00401778T ATE445164T1 (de) | 2000-06-22 | 2000-06-22 | Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1167975B1 (de) |
AT (1) | ATE445164T1 (de) |
DE (1) | DE60043100D1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE437962T1 (de) * | 2002-10-01 | 2009-08-15 | Epigenomics Ag | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen |
EP3470535B1 (de) | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs |
WO2008133493A1 (en) * | 2007-04-27 | 2008-11-06 | Erasmus University Medical Center Rotterdam | Prediction of responsiveness to anti-estrogen treatment in breast cancer |
US20170010267A1 (en) * | 2012-10-17 | 2017-01-12 | Runlin Z MA | Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy |
CN114045336B (zh) * | 2021-09-28 | 2024-01-02 | 中国人民解放军空军军医大学 | Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9608143D0 (en) * | 1996-04-19 | 1996-06-26 | Ver Nl Kanker Inst | Assay |
US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
-
2000
- 2000-06-22 AT AT00401778T patent/ATE445164T1/de active
- 2000-06-22 DE DE60043100T patent/DE60043100D1/de not_active Expired - Lifetime
- 2000-06-22 EP EP00401778A patent/EP1167975B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1167975A1 (de) | 2002-01-02 |
DE60043100D1 (de) | 2009-11-19 |
EP1167975B1 (de) | 2009-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
IL149922A (en) | Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist | |
DE60134178D1 (de) | Trp8 krebsmarker | |
DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
DK0917571T3 (da) | Hidtil ukendt agoutirelateret gen | |
BR0209646A (pt) | genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos | |
FI113377B (fi) | Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa | |
ATE352639T1 (de) | Antisense modulation der expression von integrin alpha 4 | |
ATE445164T1 (de) | Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie | |
BRPI0418229A (pt) | genes do ciclo celular e métodos corrrelatos de uso | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
ATE557092T1 (de) | Bv8-nukleinsäuren und polypeptide mit mitogener aktivität | |
DE69943129D1 (de) | Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs | |
DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
MXPA05006034A (es) | Proteina de duplicacion. | |
WO2002064023A3 (en) | Fra-1 expression in brain cancer | |
TW200501988A (en) | Nucleic acids, polypeptides, and methods for modulating apoptosis | |
DE69619683T2 (de) | Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv | |
DE69734143D1 (de) | Neue methoden zur charakterisierung von verbindungen, welche die stf-1 expression in inselzellen der bauchspeicheldrüse stimuliert | |
DE602005021159D1 (de) | Bakteriophagen- und prophagen-proteine in der krebsgentherapie | |
ATE466958T1 (de) | Klassifizierung von kolonkrebs | |
DE60230684D1 (de) | Sak: modulation der zellproliferation zur krebsbehandlung | |
WO2003106648A3 (en) | COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS | |
ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
DE69738433D1 (de) | Rezeptor-tyrosine-kinase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1167975 Country of ref document: EP |